ARTICLE | Finance
More biotechs queue up to go public: Public Equity Report
Plus: Erasca raises $632.5M follow-on to accelerate pivotal trials of RAS inhibitor
July 17, 2026 6:05 PM UTC
At least five private companies started their journey toward the public markets this week: four filed for traditional IPOs on NASDAQ, while a fifth proposed a reverse merger.
The four S-1 filers were neurology company Apnimed, immunology play Attovia, cardiovascular company Braveheart Bio, and metabolic company Vogenx. ...